Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of KSP-0930 in narcolepsy type 1
jRCT2071260010Phase 1Recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of KSP-0930 in narcolepsy type 1 (NT1), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoints: Safety (adverse events and adverse drug reactions) and Pharmacokinetic profile of KSP-0930. Started May 2026; status: recruiting.
02
Drugs
KSP-0930
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on jRCT2071260010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260010.